CORDIS
EU research results

CORDIS

English EN
Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse

Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse

Objective

Chromosomal instability (CIN), the inability to correctly segregate sister chromatids during mitosis, is a hallmark of cancer cells. Overexpression of the mitotic checkpoint protein Mad2, commonly found in human tumors, leads to CIN and the development of aneuploid tumors in mouse models. However, recent observations from various laboratories suggest that aneuploidy can promote or suppress tumorigenesis. Therefore understanding the relationship between aneuploidy and tumor formation, identifying in what context aneuploidy acts oncogenically and those in which it acts as a tumor suppressor, is thus vital if we want to make progress in battling cancer. We propose to generate regulatable mouse models that recapitulate the aneuploidy state of human tumors, using state-of–the–art mouse genetic strategies, to investigate the role of CIN in promoting or suppressing tumorigenesis.
Moreover, CIN has been shown to facilitate escape from oncogene addiction (the dependence of tumor cells on their initiating lesion for survival) and may be responsible for tumor relapse after targeted therapies. Due to the clinical relevance of these findings, this proposal aims to investigate how CIN potentiates oncogene independence. It is possible that some CIN cells in the primary tumor are already independent of the initiating oncogene prior to treatment. Alternatively, CIN cells are more susceptible of acquiring additional mutations and evolve to become independent of the initiating lesion. We propose to develop a highly innovative three-dimensional in vitro culture system to isolate and characterize these surviving cells to further eliminate them.
It is necessary to understand the molecular mechanisms that lead to CIN and the consequences it has in tumor initiation, suppression and relapse, hoping that the genes or proteins identified could be targeted therapeutically. We believe that answers to these specific aims will have important consequences for the treatment of human tumors.

Principal Investigator

Rocio Sotillo Roman (Dr.)

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Address

Im Neuenheimer Feld 280
69120 Heidelberg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 958 737,05

Principal Investigator

Rocio Sotillo Roman (Dr.)

Administrative Contact

Ina Wiest (Dr.)

Beneficiaries (2)

Sort alphabetically

Sort by EU Contribution

Expand all

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

EU Contribution

€ 958 737,05

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 541 262,95

Project information

Grant agreement ID: 281614

Status

Closed project

  • Start date

    1 February 2012

  • End date

    31 January 2018

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 1 500 000

  • EU contribution

    € 1 500 000

Hosted by:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany